Table 3.

Association Between the Prevalence of Metachronous ACN and Baseline Findings Stratified by Interval Between Examinations (Lag Time)

Lag time (y)	Prevalence of metachronous ACN, % (n/N)		aOR (95% CI) (referent = White)	P value
	Non-Hispanic Blacks	Non-Hispanic Whites
ACN (malignant + advanced polyps)
≤3	11.0 (10/91)	15.7 (19/121)	0.66 (0.29–1.52)	.33
4–5	7.8 (6/77)	9.1 (8/88)	0.95 (0.30–2.97)	.82
>5	11.3 (6/53)	11.9 (5/42)	1.01 (0.27–3.81)	.95
Total	10.0 (22/221)	12.8 (32/251)	0.77 (0.43–1.37)	.37
Malignant polyps
≤3	0.0 (0/11)	6.2 (1/16)	–	1.00
4–5	0.0 (0/1)	0.0 (0/1)	–	–
>5	0.0 (0/3)	0.0 (0/1)	–	–
Total	0.0 (0/15)	5.6 (1/18)	–	1.00
Advanced polyps (adenomas + serrated polyps +both)
≤3	12.5 (10/80)	17.1 (18/105)	0.69 (0.30–1.63)	.38
4–5	7.9 (6/76)	9.2 (8/87)	0.95 (0.30–2.95)	.78
>5	12.0 (6/50)	12.2 (5/41)	1.06 (0.28–3.98)	.98
Total	10.7 (22/206)	13.3 (31/233)	0.80 (0.44–1.43)	.40
Hyperplastic polyps ≥ 10 mm
≤3	0.0 (0/0)	0.0 (0/3)	–	–
4–5	100.0 (1/1)	0.0 (0/4)	–	.20
>5	0.0 (0/2)	0.0 (0/4)	–	–
Total	33.3 (1/3)	0.0 (0/11)	–	.21
Multiplicity (≥ 3 nonadvanced adenomas only)
≤3	3.8 (1/26)	4.0 (1/25)	–	.98
4–5	7.7 (4/52)	8.1 (5/62)	1.05 (0.25–4.41)	.94
>5	2.9 (1/35)	28.6 (6/21)	0.08 (0.01–0.74)	.01
Total	5.3 (6/113)	11.1 (12/108)	0.44 (016–1.23)	.12
1–2 Nonadvanced polyps (adenomas + serrated polyps + both)
≤3	4.9 (4/81)	9.1 (9/99)	0.51 (0.15–1.76)	.28
4–5	2.8 (4/143)	6.4 (12/188)	0.43 (0.13–1.41)	.13
>5	7.7 (26/339)	3.8 (12/320)	2.14 (1.05–4.35)	.03
Total	6.0 (34/563)	5.4 (33/607)	1.12 (0.68–1.84)	.66
Normal/nonneoplastic polyps/other
≤3	5.7 (6/106)	6.4 (8/125)	1.15 (0.36–3.66)	.81
4–5	7.9 (6/76)	10.1 (10/99)	0.75 (0.26–2.20)	.62
>5	6.2 (11/177)	5.1 (15/293)	1.22 (0.55–2.73)	.62
Total	6.4 (23/360)	6.5 (34/523)	0.98 (0.57–1.70)	.95